Back to top
more

Zoetis (ZTS)

(Delayed Data from NYSE)

$169.56 USD

169.56
4,088,408

+0.12 (0.07%)

Updated May 31, 2024 04:00 PM ET

After-Market: $169.64 +0.08 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 250)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

Zoetis Inc. came into existence following Pfizer’s decision to spin off its animal health business. he company is a leader in the discovery, development, manufacture and commercialization of animal health medicines, vaccines and diagnostic products with a focus on both livestock and companion animals. Zoetis has a diversified business, which caters to eight core species — cattle, swine, poultry, fish and sheep (collectively, livestock) and dogs, cats and horses (collectively, companion animals).

Is Zoetis (ZTS) Stock Outpacing Its Medical Peers This Year?

Is (ZTS) Outperforming Other Medical Stocks This Year?

Zoetis (ZTS) Receives EC Approval for Simparica Trio in Dogs

Zoetis' (ZTS) leading animal health portfolio gets a boost with the approval of Simparica Trio.

ASRT vs. ZTS: Which Stock Is the Better Value Option?

ASRT vs. ZTS: Which Stock Is the Better Value Option?

Kinjel Shah headshot

Buy These 7 Small Drugmakers to Boost Your Portfolio's Health

Successful innovation resulting in new drug approvals, important advances in clinical studies, frequent collaborations and M&A activity have kept small drugmakers afloat in a competitive market.

Is Zoetis (ZTS) Stock Outpacing Its Medical Peers This Year?

Is (ZTS) Outperforming Other Medical Stocks This Year?

Kinjel Shah headshot

Small Drug Stock Outlook: Innovation Holds the Key to Growth

Successful innovation resulting in new drug approvals, important advances in clinical studies, frequent collaborations and M&A activity have kept small drugmakers afloat in a competitive market.

Why Is Zoetis (ZTS) Up 5.5% Since Last Earnings Report?

Zoetis (ZTS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?

Style Box ETF report for FTCS

ASRT vs. ZTS: Which Stock Should Value Investors Buy Now?

ASRT vs. ZTS: Which Stock Is the Better Value Option?

The Zacks Analyst Blog Highlights: Procter & Gamble, T-Mobile, Zoetis, Autodesk and FedEx

The Zacks Analyst Blog Highlights: Procter & Gamble, T-Mobile, Zoetis, Autodesk and FedEx

Mark Vickery headshot

Top Stock Reports for Procter & Gamble, T-Mobile & Zoetis

Today's Research Daily features updated research reports on 16 major stocks, including Procter & Gamble (PG), T-Mobile (TMUS) and Zoetis (ZTS).

Is Zoetis (ZTS) Stock Outpacing Its Medical Peers This Year?

Is (ZTS) Outperforming Other Medical Stocks This Year?

Mitchell Moore headshot

Bayer Sells Animal Health Division to Elanco: Now What?

On Tuesday, Bayer (BAYRY) announced the sale of its animal-health division to American competitor Elanco (ELAN), for a net price of $7.6 billion. The deal is expected to close in mid-2020 after regulatory approval.

HKMPF or ZTS: Which Is the Better Value Stock Right Now?

HKMPF vs. ZTS: Which Stock Is the Better Value Option?

Pacira (PCRX) Q2 Earnings and Revenues Surpass Estimates

Pacira (PCRX) rides high on both earnings and revenue beat in the second quarter of 2019. Moreover, Exparel drives year-over-year growth.

Has Zoetis (ZTS) Outpaced Other Medical Stocks This Year?

Is (ZTS) Outperforming Other Medical Stocks This Year?

Zoetis (ZTS) Hits Fresh High: Is There Still Room to Run?

Zoetis (ZTS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zoetis (ZTS) Looks Good: Stock Adds 7.6% in Session

Zoetis (ZTS) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

Zoetis (ZTS) Beats on Earnings in Q2, Lifts 2019 Guidance

Zoetis (ZTS) beats on earnings and sales in the second quarter and also raises its 2019 outlook.

Zoetis (ZTS) Tops Q2 Earnings and Revenue Estimates

Zoetis (ZTS) delivered earnings and revenue surprises of 9.76% and 2.07%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Zoetis (ZTS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Zoetis (ZTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zoetis (ZTS) to Report Q2 Earnings: What's in the Cards?

Investors will focus on top- and bottom-line numbers along with other pipeline updates, when Zoetis reports Q2 results.

CTLT vs. ZTS: Which Stock Is the Better Value Option?

CTLT vs. ZTS: Which Stock Is the Better Value Option?

The Zacks Analyst Blog Highlights: MarketAxess, Copart, WellCare Health, Zoetis and Intuit

The Zacks Analyst Blog Highlights: MarketAxess, Copart, WellCare Health, Zoetis and Intuit